

Review

Open Access



Oncologic outcomes in robot-assisted radical cystectomy: Where do we stand in 2021?

Brady L. Miller, Mark Pachorek, Andre-Philippe Sam, Bertram Yuh, Clayton S. Lau

Division of Urologic Oncology, Department of Surgery, City of Hope National Comprehensive Cancer Center, Duarte, CA 91010, USA.

Correspondence to: Dr. Clayton S. Lau, Division of Urology, Department of Surgery, City of Hope, 1500 E. Duarte Rd, MALP #1211, Duarte, CA 91010, USA. E-mail: clau@coh.org

How to cite this article: Miller BL, Pachorek M, Sam AP, Yuh B, Lau CS. Oncologic outcomes in robot-assisted radical cystectomy: Where do we stand in 2021? *Mini-invasive Surg* 2021;5:24. <https://dx.doi.org/10.20517/2574-1225.2021.25>

Received: 24 Feb 2021 **First Decision:** 31 Mar 2021 **Revised:** 7 Apr 2021 **Accepted:** 12 Apr 2021 **Published:** 8 May 2021

Academic Editor: Giulio Belli **Copy Editor:** Xi-Jun Chen **Production Editor:** Xi-Jun Chen

Abstract

Robot-assisted radical cystectomy is an alternative to the standard open surgical approach and has been increasingly used to surgically treat bladder cancer. Data on oncologic outcomes for the robotic approach have matured, and now intermediate and long-term oncologic outcomes are available. This review focuses on oncologic outcomes of the robotic approach with a focus on recent data and high-quality studies. Based on the current literature available, there are no consistent differences between the robotic and open approaches with respect to positive margin rates, lymph node yields, recurrence patterns, or recurrence free, cancer-specific, and overall survival. If oncologic surgical principles are adhered to, excellent oncologic outcomes are achievable with the robotic approach.

Keywords: Urinary bladder neoplasms, radical cystectomy, robotic radical cystectomy, oncologic outcomes, robotics, recurrence, survival

INTRODUCTION

Radical cystectomy and pelvic lymph node dissection is standard of care for surgically eligible patients with non-metastatic muscle-invasive bladder cancer, and is a preferred treatment for select patients with high risk of non-muscle invasive disease^[1,2]. While open radical cystectomy has been the recognized gold standard for years, robot-assisted radical cystectomy (RARC) has become increasingly popular. Initially



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

described by Menon *et al.*^[3] in 2003, utilization of RARC increased from 0.7% in 2002 to 18.5% in 2012 in the United States^[4]. Advantages of the robotic approach relative to open radical cystectomy (ORC) include reduced blood loss, favorable transfusion rate and shorter length of stay^[5].

Here, we review pertinent oncologic outcomes in the current RARC literature. We queried the PubMed electronic database in January 2021 for studies that report on oncologic outcomes for RARC. An emphasis was placed on randomized controlled trials, as well as contemporary comparative open approach cohorts, large single institution surgical series, multi-center initiatives and systematic reviews. A list of the major studies considered in this review is found in [Table 1](#).

NODAL YIELD

Lower nodal yield and positive surgical margin status are independently associated with worse OS after adjustment for neoadjuvant chemotherapy and pathologic factors. In fact, nodal yields of 10-14 have been proposed as a marker of surgical quality^[33]. Professional guidelines and best practice statements are less quantitatively prescriptive^[1,34], as patient, clinical and pathologic factors can influence lymph node yield. In a 2015 systematic review, Yuh *et al.*^[35] assessed 105 papers and found that median yield for a robotic approach was 19 lymph nodes (range: 3-55) with cumulative analyses finding no difference *vs.* ORC. Nodal yields are directly related to the surgical dissection template chosen, whether standard or extended. Among robotic surgeons, high volume surgeons and institutional volume were independently associated with performance of extended template dissections^[36].

Several RCTs have found comparable nodal yields between RARC and ORC [[Table 2](#)]. Nix *et al.*^[11] found mean LN yields of 19 *vs.* 18 in RARC *vs.* ORC ($P = 0.51$) using a standard dissection template. In the largest clinical trial, RAZOR investigators found similar median lymph node yields of 23.3 for RARC with 51% utilizing an extended template, and 25.7 for ORC with 55% utilizing an extended template ($P = 0.13$)^[6]. Other smaller RCTs reported similar findings^[8,9]. Several recent meta-analyses did not assess nodal yield^[37,38].

Considering the abundance of data, adequate lymph node yields are achievable via robotic platforms, including extended and super extended templates. Maintenance of oncologic principles including performance of a meticulous dissection within pre-defined anatomic boundaries of a template appears to be more important than surgical approach.

POSITIVE MARGIN RATE

Positive surgical margin (PSM) rate is a measure of local disease burden, an independent predictor of survival, and can be a measure of surgical quality^[33,39,40]. Early criticism of minimally invasive approaches was that there was risk of higher positive margin rates in locally advanced tumors, as evidenced by a single non-controlled, non-comparative retrospective study^[32]. It was theorized that the lack of tactile feedback and learning curve was potential explanations^[35,41].

These early criticisms have largely been refuted. A systematic review showed that PSM rate was low in pT2 disease (< 1.5%) and 0%-25% in pT3 disease or higher, without any significant difference between ORC and RARC in a cumulative analysis of 17 studies^[35]. Interestingly, PSM did not appear to decrease with sequential case numbers or institutional volume^[32], a finding that may reflect surgeons' willingness to take on more difficult cases with experience^[35]. As a result of these early robotic data and historical open cystectomy series, acceptable PSM rates for robotic surgeons were proposed as < 3% for pT2, < 10% for pT3, < 25% for pT4 and < 7% overall^[34,40].

Table 1. Selected studies evaluating oncologic outcomes after robot-assisted radical cystectomy

Ref.	Year	Comparison	Study design	Setting	Primary outcome	Pertinent secondary outcome(s)
Comparative studies, randomized						
RAZOR trial, multiple authors ^[6,7]	2020, 2018	ORC vs. RARC	RCT	Multi center	2-year PFS	TTR, PFS, OS
CORAL trial, Khan et al. ^[8]	2020	ORC vs. RARC vs. LRC	RCT	Single center	5-year RFS, CSS, OS	Surgical margin, recurrence patterns
Bochner et al. ^[9]	2018	ORC vs. RARC	RCT	Single center	90-day complication	RFS, CSS, OS, recurrence patterns
Parekh et al. ^[10]	2012	ORC vs. RARC	RCT	Single center	Surgical margin Total lymph node yield	Quality of life Functional recovery
Nix et al. ^[11]	2010	ORC vs. RARC	RCT	Single center	Lymph node yield	Demographics, perioperative, pathologic results, narcotic use
Comparative studies, non-randomized						
RACE study, Wijburg et al. ^[12]	2021	ORC vs. RARC	Prospective	Multi center	90-day complication	HRQOL, complications, clinical outcomes including surgical margin
Asil et al. ^[13]	2021	ORC vs. RARC	Retrospective	Multi center	Intraoperative and postoperative endpoints	Surgical margin, lymph node yield
Ip et al. ^[14]	2020	ORC vs. RARC	Retrospective	Single center	RFS, OS	Perioperative and pathologic outcomes
Zhang et al. ^[15]	2020	ORC vs. RARC	Retrospective	Single center	Perioperative outcomes, complications	Pathologic outcomes, overall survival
Faraj et al. ^[16]	2019	ORC vs. RARC	Retrospective	Single center	RFS, OS	Recurrence patterns, predictors of primary outcome
Moschini et al. ^[17]	2019	ORC vs. RARC	Retrospective	Multicenter	Surgical margin status	Predictors of surgical margin status
Simone et al. ^[18]	2018	ORC vs. RARC, ICUD only	Retrospective	Single center	RFS, CSS, OS	Complications, perioperative and pathologic outcomes
Hanna et al. ^[19]	2018	ORC vs. RARC	Retrospective	Population registry	Intraoperative and postoperative endpoints	Descriptors and predictors of robotic surgical approach
Gandagli et al. ^[20]	2016	ORC vs. RARC	Retrospective	Multi center	RFS, CSS, OS	Complications, perioperative and pathologic outcomes, recurrence
Tan et al. ^[21]	2016	ORC vs. RARC	Retrospective	Single center	RFS	Recurrence patterns, CSS, OS
Matulewicz et al. ^[22]	2016	ORC vs. RARC	Retrospective	Population registry	Surgical margin status, lymph node yield	Primary outcome variables as predictors of survival
Nguyen et al. ^[23]	2015	ORC vs. RARC	Retrospective	Single center	RFS	Recurrence patterns at 2 years
Atmaca et al. ^[24]	2015	ORC vs. RARC, ICUD only	Retrospective	Single center	Demographics, functional, intraoperative outcomes	Surgical margin, lymph node yield
Non-comparative studies						
IRCC, Elsayed et al. ^[25]	2021	RARC only	Retrospective	Multicenter	RFS, LRFS, DMFS, OS	Recurrence patterns, predictors of recurrent free survival
Brassetti et al. ^[26]	2020	RARC, ICUD only	Retrospective	Multicenter	RFS, CSS, OS	Surgical margin, lymph node yield, predictors of survival
IRCC, Hussein et al. ^[27]	2019	RARC only	Retrospective	Multicenter	10-year RFS, CSS, OS	Surgical margin, lymph node yield, predictors of survival

IRCC, Hussein <i>et al.</i> ^[28]	2017	RARC only	Retrospective	Multicenter	Incidence of early oncologic failure (any disease relapse < 3 mo s/p RARC)	Recurrence patterns, adherence to oncologic principles, predictors of early oncologic failure
ERUS, Collins <i>et al.</i> ^[29]	2017	RARC, ICUD only	Retrospective	Multicenter	RFS	Recurrence patterns
IRCC, Raza <i>et al.</i> ^[30]	2015	RARC only	Retrospective	Multicenter	5-year RFS, CSS, OS	Surgical margin, lymph node yield, predictors of survival
IRCC, Hellenthal <i>et al.</i> ^[31]	2011	RARC only	Retrospective	Multicenter	Proportion of RARC w/lymphadenectomy performed	Lymph node yield, predictors of lymphadenectomy performance
IRCC, Hellenthal <i>et al.</i> ^[32]	2010	RARC only	Retrospective	Multicenter	Surgical margin status	Predictors of surgical margin status

RAZOR: Randomized open vs. robotic cystectomy; ORC: open radical cystectomy; RARC: robotic assisted radical cystectomy; RCT: randomized controlled trial; TTR: time to recurrence; RFS: recurrence free survival; PFS: progression free survival; CSS: cancer specific survival; OS: overall survival; CORAL: controlled three-arm trial of Open, Robotic, and laparoscopic radical cystectomy; RACE: radical cystectomy evaluation; HRQOL: health-related quality of life; IRCC: International Robotic Cystectomy consortium; LRFS: local recurrence free survival; DMFS: distant metastasis free survival; ICUD: intracorporeal urinary diversion; ERUS: European Association of Urology Robotic Urology Section; LRC: laparoscopic radical cystectomy.

Since then, multiple RCTs and retrospective comparative studies offer additional insight that robotic cystectomy can meet these standards of surgical quality. The RAZOR trial showed overall PSM rates of 5% (ORC) *vs.* 6% (RARC), $P = 0.6$ without any difference in pathologic stage between the groups. Of those with PSMs, 7/9 (78%) in RARC and 5/7 (71%) in ORC were T3 or above^[6]. Two smaller RCTs also found no difference in PSM rate between open and robotic approaches^[8,9]. A meta-analysis compiling 541 patients from RCTs showed no difference in PSM rates between RARC and ORC (RR = 1.2; 95%CI: 0.6-2.4)^[37]. Additionally, one non-randomized comparative study found significantly increased PSM rate for ORC (18%) *vs.* RARC (6%) in an inversed probability weighted population despite similar pathologic staging, though when further specified by site of positive margin these results were not significantly different^[12]. Multiple other non-randomized comparative studies have not found significant differences in PSM rate by approach^[13-17,19,20,22-24].

Collectively, the above data suggest favorable PSM rates are achievable via the robotic platform and are in alignment with standards of surgical quality set forth by best practices statements^[34]. Regardless of surgical approach, the largest determinant of PSM rates is local disease stage.

RECURRENCE PATTERNS

Recurrence of bladder cancer after radical cystectomy is dependent on tumor and nodal stage, and ranges from 20% to 30% in pT2 disease, 40% for pT3, > 50% for pT4 and approximately 70% in pN1 disease or greater^[42]. Other independent predictors of tumor recurrence include lymphovascular invasion and positive soft tissue margins^[43]. Recurrences generally occur within the first 2-3 years and predict worse overall survival (OS)^[44].

Recurrence is generally classified as local, often referring to the cystectomy bed and within the pelvic lymph node template, or distant. Atypical patterns in MIS generally refer to peritoneal carcinomatosis, abdominal wall/port site metastases and extra pelvic lymph node recurrences, which have been described but are rare. In fact, a systematic review of 1094 studies found only 5 that reported port site metastasis^[45]. Proposed contributors of atypical recurrence patterns in MIS include depressive local immunologic factors and/or enhanced tumor dissemination related to pneumoperitoneum, breach of oncologic operative principles,

Table 2. Oncologic outcomes from selected studies after robot-assisted radical cystectomy

Ref. and study acronym	Year	Surgical approach	Cases, (n)	PSM, n (%)	Lymph node yield, mean (SD) or median (IQR or range)	RFS	CSS	OS
Comparative studies, randomized								
RAZOR trial, multiple authors ^[6,7]	2020, 2018	ORC	152	7 (5)	25.7 (SD 14.5)	65%, 3 yr	nr	69%, 3 yr
		RARC	150	9 (6)	23.3 (SD 12.5)	68%, 3 yr	nr	74%, 3 yr
CORAL trial, Khan et al. ^[8]	2020	ORC	20	2 (10)	18.5 (IQR 14-25)	60%, 5 yr	64%, 5 yr	55%, 5 yr
		RARC	20	3 (15)	14.5 (IQR 11-21)	58%, 5 yr	68%, 5 yr	65%, 5 yr
		LRC	19	1 (5)	15.5 (IQR 12-22)	71%, 5 yr	69%, 5 yr	61%, 5 yr
Bochner et al. ^[9]	2018	ORC	58	3 (5)	29 (IQR 22-38)	59%, 5 yr	80%, 5 yr [#]	65%, 5 yr [#]
		RARC	60	2 (3)	31 (IQR 23-37)	64%, 5 yr	75%, 5 yr [#]	65%, 5 yr [#]
Parekh et al. ^[10]	2012	ORC	20	1 (5)	23 (IQR 15-28)	nr	nr	nr
		RARC	20	1 (5)	11 (IQR 9-22)	nr	nr	nr
Nix et al. ^[11]	2010	ORC	20	0 (0)	18 (range 8-30)	nr	nr	nr
		RARC	21	0 (0)	19 (range 12-30)	nr	nr	nr
Comparative studies, non-randomized								
RACE study, Wijburg et al. ^[12]	2021	ORC	168	nr (18)*	13 (IQR 9-18)	75%, 1 yr	nr	nr
		RARC	180	nr (6)	15 (IQR 11-21)	76%, 1 yr	nr	nr
Asil et al. ^[13]	2021	ORC	31	1 (3)	22 (nr)	nr	nr	nr
		RARC	61	9 (15)	Range 22-25	nr	nr	nr
Ip et al. ^[14]	2020	ORC	159	23 (14)	20 (SD 14)*	75%, 5 yr [#]	nr	65%, 5 yr [#]
		RARC	73	8 (11)	12 (SD 8)	80 %, 5 yr [#]	nr	70%, 5 yr [#]
Zhang et al. ^[15]	2020	ORC	272	22 (8)	nr	nr	nr	55%, 5 yr
		RARC	676	34 (5)	nr	nr	nr	58%, 5 yr
Faraj et al. ^[16]	2019	ORC	278	15 (5)	12 (IQR 9-18)*	63%, 10 yr	nr	46%, 10 yr
		RARC	203	7 (3)	18 (IQR 14-24)	70%, 10 yr	nr	40%, 10 yr
Moschini et al. ^[17]	2019	ORC	1666	160 (10)	16 (10-24)	nr	nr	nr
		RARC	870	112 (13)	18 (12-25)	nr	nr	nr
Simone et al. ^[18]	2018	RARC, ICUD only	64	0 (0)	33.4 (SD 12.3)	79%, 4 yr	85%, 4 yr	82%, 4 yr
		ORC	46	0 (0)	31.3 (SD 14.6)	73%, 4 yr	86%, 4 yr	80%, 4 yr
Hanna et al. ^[19]	2018	ORC	7513	(10.7)	12 (IQR 7-20)*	nr	nr	nr
		RARC	2048	(9.3)	17 (IQR 10-25)	nr	nr	nr
Gandagli et al. ^[20]	2016	ORC	230	31 (13)	13 (IQR 9-17)	57%, 5 yr	62%, 5 yr	58%, 5 yr
		RARC	138	12 (9)	12 (IQR 8-17)	54%, 5 yr	74%, 5 yr	59%, 5 yr
Tan et al. ^[21]	2016	ORC	90	17 (19)*	12.6 (SD 10.9)	70%, 2 yr	81%, 2 yr	74%, 2 yr

		RARC	94	6 (8)	14.9 (SD 10.0)	79%, 2 yr	84%, 2 yr	84%, 2 yr
Matulewicz <i>et al.</i> ^[22]	2016	ORC	9639	(13)	11 (IQR 5-19)*	nr	nr	nr
		RARC	2397	(11)	16 (IQR 9-25)	nr	nr	nr
Nguyen <i>et al.</i> ^[23]	2015	ORC	120	15 (13)*	20 (IQR 11-27)	60%, 5 yr [#]	nr	nr
		RARC	263	16 (6)	21 (IQR 13-28)	70%, 5 yr [#]	nr	nr
Atmaca <i>et al.</i> ^[24]	2015	ORC	42	1 (2)	17 (SD 13.5)	nr	nr	nr
		RARC, ICUD only	32	2 (6)	25 (SD 9.7)	nr	nr	nr
Non-comparative studies								
IRCC, Elsayed <i>et al.</i> ^[25]	2021	RARC only	2107	nr	nr	66%, 5 yr	nr	60%, 5 yr
Brassetti <i>et al.</i> ^[26]	2020	RARC, ICUD only	113	9 (8)	36 (IQR 28-45)	58%, 5 yr	61%, 5 yr	54%, 5 yr
IRCC, Hussein <i>et al.</i> ^[27]	2019	RARC only	446	30 (7)	14 (IQR 9-22)	59%, 10 yr	65%, 10 yr	35%, 10 yr
ERUS, Collins <i>et al.</i> ^[29]	2017	RARC, ICUD only	717	34 (4)	18 (IQR 13-25)	75%, 2 yr		
IRCC, Raza <i>et al.</i> ^[30]	2015	RARC only	702	55 (8)	16 (IQR 10-24)	67%, 5 yr	75%, 5 yr	50%, 5 yr
IRCC, Hellenthal, <i>et al.</i> ^[31]	2011	RARC only	527	nr	17.8 (range 0-68)	nr	nr	nr
IRCC, Hellenthal, <i>et al.</i> ^[32]	2010	RARC only	513	35 (6.8)	nr	nr	nr	nr

[#]Visual estimate based on Kaplan Meier curves provided in paper (specific numbers not provided by reference in text). * $P < 0.05$. PSM: Positive surgical margin; SD: standard deviation; IQR: interquartile range; RFS: recurrence free survival; CSS: cancer-specific survival; OS: overall survival; ORC: open radical cystectomy; RARC: robotic assisted radical cystectomy; LRC: laparoscopic radical cystectomy; nr: not reported; ICUD: intracorporeal urinary diversion; RAZOR: randomized open vs. robotic cystectomy; CORAL: controlled three-arm trial of open, robotic, and laparoscopic radical cystectomy; RACE: radical cystectomy evaluation; IRCC: International Robotic Cystectomy Consortium; ERUS: European Association of Urology Robotic Urology Section.

or variant lymphatic dissemination related to robotic technique^[23].

Nguyen *et al.*^[23] reported atypical patterns of recurrence in a non-randomized single center comparative study of ORC vs. RARC, including higher incidence of peritoneal carcinomatosis (21% vs. 8%) and extra pelvic lymph node (23% vs. 15%) [Table 3]. However, the denominator of these estimated proportions was distant recurrences and not overall recurrence, as is typically reported. It was additionally notable that distant recurrences were not significantly different between the two approaches, and the authors noted that selection bias may have contributed to these findings. The same group published a follow up study consisting of 310 patients and found that predictors of distant recurrences, peritoneal carcinomatosis and extra pelvic lymph node metastases did not significantly differ and concluded that tumor biology is likely the chief influencer of atypical recurrence, not surgical approach^[46]. Bochner *et al.*^[9] later found that there was variation in location of recurrence and that RARC resulted in greater numbers of recurrences in the abdomen and pelvis. However, this only achieved significance when pooled and stratification of abdominal recurrences as separate from distant and local recurrences is controversial and of unclear clinical significance^[47]. Notably, the study was not powered to determine differences in patterns of recurrence.

Table 3. Recurrence patterns from selected studies

Ref.	Year	Surgical approach	Cases (n)	Local recurrence ^a , n (%)	Distant recurrence ^b , n (%)	Atypical recurrence ^c			Significantly different?	Comments
						Peritoneal carcinomatosis, n (%)	Abdominal wall/port site, n (%)	Extra pelvic lymph nodes, n (%)		
Comparative studies, randomized										
RAZOR trial, multiple authors ^[6,7]	2020, 2018	ORC	152	3 (2.0)	25 (16.4)	1 (0.7)	1 (0.7)	9 (5.9)	No	Largest RCT to date
CORAL trial, Khan et al. ^[8]	2020	RARC	150	6 (4.0)	22 (14.7)	2 (1.3)	0	9 (6.0)	No	Small sample size. Distant recurrences reported in aggregate only, not shown here
		ORC	20	3 (15.0)	nr	nr	nr	nr		
		RARC	20	3 (15.0)	nr	nr	nr	nr		
Bochner et al. ^[9]	2018	ORC	58	5 (8.6)	27 (46.6)	2 (3.4)	0	10 (17.2)	No ^d	Not powered to detect differences in recurrence patterns
		RARC	60	17 (28.3)	20 (33.0)	2 (3.3)	5 (8.3)	5 (8.3)		
Comparative studies, non-randomized										
Faraj et al. ^[16]	2019	ORC	278	19 (7)	64 (23)	5 (1.8)	0	11 (4.0)	No	Large single institutional study
		RARC	203	12 (6)	40 (20)	4 (2.0)	0	4 (2.0)		
Tan et al. ^[21]	2016	ORC	90	17 (19)	25 (28)	3 (3)	1 (1)	2 (2)	No	Intracorporeal diversions in all robotic cases
		RARC	94	11 (12)	8 (9)	2 (2)	1 (1)	3 (3)		
Nguyen et al. ^[23]	2015	ORC	79	15/65 (23)	26/73 (36)	2/26 (8)	nr	4/26 (15)	Yes	Denominator is distant recurrence, as listed in the reference
		RARC	158	24/136 (18)	43/147 (29)	9/43 (21)	nr	10/43 (23)		
Non-comparative studies										
IRCC, Elsayed et al. ^[25]	2021	RARC only	2107	241 (11)	382 (18)	26 (1.2)	25 (1.2)	109 (5.2)	n/a	RARC not associated with different patterns or higher recurrence relative to historic ORC series
IRCC, Hussein et al. ^[27]	2019	RARC only	446	69 (15)	97 (22)	6 (1)	5 (1)	21 (5)	n/a	Analysis restricted to patients with > 10 years follow up
Collins et al. ^[29]	2017	RARC, ICUD only	717	78 (10.7)	128 (17.8)	5 (0.7)	2 (0.3)	47 (6.6)	n/a	Totally intracorporeal urinary diversion cohort

^aLocal recurrence defined as any recurrence in the cystectomy bed or lymph node dissection template. ^bDistant recurrence defined as any recurrence which is not local or atypical. ^cThough sometimes reported in the referenced studies as a subset of distant recurrences, atypical recurrences reported here are mutually exclusive of local and distant recurrence. ^dThe difference in local recurrence rates did not meet conventional levels of significance (sHR = 0.36; 95%CI: 0.11-1.12, P = 0.077). Similarly, the difference in the rate of abdominal recurrence did not reach statistical significance (sHR = 0.38; 95%CI:0.07-1.96; P = 0.2). However, when the pelvic and abdominal recurrences were combined into a single group representing local/regional recurrence, the ORC group showed significantly less local/regional recurrence compared to RARC (sHR = 0.34; 95%CI: 0.12-0.93; P = 0.035)". RAZOR: randomized open vs. robotic cystectomy; ORC: open radical cystectomy; RARC: robotic assisted radical cystectomy; RCT: randomized controlled trial; CORAL: controlled three-arm trial of open, robotic, and laparoscopic radical cystectomy; IRCC: International Robotic Cystectomy Consortium; ICUD: intracorporeal urinary diversion; nr: not reported.

Multiple studies have since demonstrated that recurrence patterns do not differ by surgical approach. The RAZOR trial found no significant difference between ORC and RARC in recurrence patterns and showed low overall local recurrence rates (2% vs. 4%). Rare atypical recurrences were also observed in the ORC arm and did not differ between approaches^[7]. A large non-randomized single center comparative study from Mayo Clinic in Arizona showed similar rates of local, distant and rare atypical recurrences^[16]. An institutional report of ~180 cases, 90 of which were robotic with intracorporeal diversion, showed a low rate of atypical recurrences with no difference between surgical approaches^[21]. An IRCC study of 2107 pts showed slightly higher local recurrence (11%, citing a greater percentage of extravesical disease and variant histology in their cohort) with atypical recurrence patterns similar to ORC series and those of the RAZOR trial^[7,25]. A separate IRCC analysis found that tumor factors rather than those related to surgical approach were predictive of early recurrence after cystectomy and also showed that surgeons in their cohort reported a very low rate of divergence from oncologic principles^[28]. Lastly, a large multi-institutional robotic cystectomy and totally intracorporeal urinary diversion cohort from the EAU Robotic Urology Section Scientific Working Group found that early recurrence rates and patterns appeared comparable to open series^[29].

If oncologic principles are followed, these aggregate data suggest that atypical recurrence is exceedingly rare and are more likely reflective of tumor biology than surgical approach.

SURVIVAL OUTCOMES

The primary measure of treatment efficacy in radical cystectomy is survival, including recurrence-free, cancer-specific and overall survival^[1]. Though reported here for reference, we would discourage direct comparison across studies as there is significant heterogeneity with respect to cancer variables (e.g., receipt of neoadjuvant chemotherapy, disease stage, and tumor histopathology), patient demographic and clinical characteristics, surgeon and institutional factors including intra-operative practices and post-operative follow up protocols, adjuvant therapies and length of follow up. This heterogeneity is reflected by a 2015 systematic review of mostly retrospective studies which demonstrated a wide range of 5-year survival estimates of DFS, CSS and OS between 53%-74%, 66%-80% and 39%-66%, respectively^[35].

Several contemporary comparative studies do offer additional limited insight, though we are only aware of 3 RCTs that report survival outcomes. RAZOR is the largest RCT reporting survival outcomes at approximately 150 patients in each arm and reports 3 year outcomes^[7]. RARC was similar compared with ORC in RFS (68% vs. 65%, $P = 0.6$) and OS (74% vs. 69%, $P = 0.3$). Bochner *et al.*^[9] found that a median follow up of 4.9 years, no differences were observed in recurrence [hazard ratio (HR) = 1.27; 95%CI: 0.69-2.36; $P = 0.4$], cancer-specific survival ($P = 0.4$), or overall survival ($P = 0.8$). However, the authors cautioned that their study was not powered to assess survival outcomes. A meta-analysis with pooled data from these two studies found that RARC and ORC may result in similar time to recurrence (HR = 1.1; 95%CI: 0.8-1.4), but the evidence of certainty was low^[37]. More recently, the CORAL study reported 5-year RFS, CSS, OS as well and found no differences in surgical approaches comparing open vs. robotic vs. laparoscopic approaches^[8]. However, their study was limited by low sample size as only 20 patients were included in each arm and included high-risk non-muscle invasive bladder cancer.

Though lacking the rigor of a controlled trial, long-term oncologic outcomes from several robotic cohorts have recently become available. Faraj *et al.*^[16] reported their 10 year survival outcomes in a single institution retrospective comparative study and found that RFS and OS were similar between ORC and RARC approaches (63% vs. 70%, $P = 0.14$ and 46% vs. 40%, $P = 0.47$ respectively). The cohorts were similar in cancer characteristics, patient demographics and clinical factors as well as intra operative practices.

Retrospective non-comparative results from the IRCC on patients with long-term follow up show RFS, CSS and OS at 10 years were 59%, 65% and 35%, consistent with historical ORC and MIS cohorts^[27]. Not surprisingly, in multivariable models, they found that survival was associated with age, positive margins, tumor/nodal stage, and adjuvant treatments. Similar results are described in a multicenter study among RARC patients with totally intracorporeal urinary diversion^[26]. A single institutional comparative study also showed similar survival in a totally intracorporeal urinary diversion robotic cohort when compared with ORC^[18].

Matured, long-term survival data from randomized controlled studies, including RAZOR, are further anticipated. Early and intermediate survival outcomes between RARC and ORC appear to be similar. Since no consistent difference in PSM rates or recurrence patterns have been found in the literature, we expect long-term survival differences to be driven largely by factors related to disease aggressiveness including stage and need for adjuvant therapies, rather than surgical approach.

FUTURE PERSPECTIVES

Nearly 20 years after the robotic approach to radical cystectomy was described^[3], RARC remains an effective and minimally invasive option for patients undergoing cystectomy that can achieve oncologic outcomes that are comparable to the gold standard open approach. Evidence-based consensus and best practices on RARC are available^[34].

There are no absolute contraindications to the robotic approach, but an early learning curve is recognized and several challenging case scenarios (e.g., large bulky tumors, history of pelvic radiation) should be preferentially managed by experienced robotic surgeons. RARC can be safely utilized in the octogenarian^[48], and oncologic outcomes are excellent in sex-sparing techniques in the female patient^[49] as well as male patient^[50]. Excellent pathologic outcomes have been described for aggressive histopathological variants which are known to present with higher tumor stage^[51]. The usage of the robotic approach to cystectomy will continue to increase as urologic surgeons become more experienced and comfortable with the platform and education becomes more commonplace in residency training programs^[4].

Though the current evidence is well-supported, it is limited by the lack of large, randomized controlled trials. We eagerly anticipate more mature, high-quality data comparing oncologic outcomes of open and robotic cystectomy. Robot-assisted radical cystectomy with intracorporeal urinary diversion *vs.* open radical cystectomy (iROC) is a multicenter prospective RCT in England randomizing 320 patients to iRARC or ORC. Accrual finished in February 2020, and oncologic outcomes of interest include atypical recurrence patterns, survival, as well as outcomes related to surgeon fatigue, cost-effectiveness and patient quality of life^[52].

CONCLUSION

Surgical quality indicators, including lymph node yield and positive surgical margin rate, are comparable between ORC and RARC. Despite an early case series of atypical recurrence patterns, contemporary comparative studies, including the largest randomized controlled trial, as well as a multi-institutional retrospective robotic cohort of > 2000 consecutive patients, show this is a rare occurrence and not associated with surgical approach. Survival outcomes appear to be similar as well, including long term survival from several comparative and non-comparative reports. Ultimately, surgeon comfort with the selected approach and adherence to oncologic principles is more important than the approach itself.

DECLARATIONS

Authors' contributions

Made substantial contributions to conception and design of the study and performed data acquisition and interpretation: Miller BL, Lau CS, Pachorek M, Yuh B, Sam AP

Performed data acquisition, as well as provided administrative, technical, and material support: Miller BL, Lau CS, Pachorek M

Availability of data and materials

Not applicable.

Financial support and sponsorship

None.

Conflicts of interest

All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Copyright

© The Author(s) 2021.

REFERENCES

1. Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO Guideline. *J Urol* 2017;198:552-9. [DOI PubMed PMC](#)
2. Chang SS, Boorjian SA, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. *J Urol* 2016;196:1021-9. [DOI PubMed](#)
3. Menon M, Hemal AK, Tewari A, et al. Nerve-sparing robot-assisted radical cystoprostatectomy and urinary diversion. *BJU Int* 2003;92:232-6. [DOI PubMed](#)
4. Hu JC, Chughtai B, O'Malley P, et al. Perioperative outcomes, health care costs, and survival after robotic-assisted versus open radical cystectomy: A National Comparative Effectiveness Study. *Eur Urol* 2016;70:195-202. [DOI PubMed](#)
5. Cai PY, Khan AI, Shoag JE, Scherr DS. Robotic radical cystectomy in the contemporary management of bladder cancer. *Urol Clin North Am* 2021;48:45-50. [DOI PubMed](#)
6. Parekh DJ, Reis IM, Castle EP, et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. *Lancet* 2018;391:2525-36. [DOI PubMed](#)
7. Venkatramani V, Reis IM, Castle EP, et al. Predictors of recurrence, and progression-free and overall survival following open versus robotic radical cystectomy: Analysis from the RAZOR trial with a 3-year followup. *J Urol* 2020;203:522-9. [DOI PubMed PMC](#)
8. Khan MS, Omar K, Ahmed K, et al. Long-term oncological outcomes from an early phase randomised controlled three-arm trial of open, robotic, and laparoscopic radical cystectomy (CORAL). *Eur Urol* 2020;77:110-8. [DOI PubMed](#)
9. Bochner BH, Dalbagni G, Marzouk KH, et al. Randomized trial comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: Oncologic outcomes. *Eur Urol* 2018;74:465-71. [DOI PubMed PMC](#)
10. Parekh DJ, Messer J, Fitzgerald J, Ercole B, Svatek R. Perioperative outcomes and oncologic efficacy from a pilot prospective randomized clinical trial of open versus robotic assisted radical cystectomy. *J Urol* 2013;189:474-9. [DOI PubMed](#)
11. Nix J, Smith A, Kurpad R, Nielsen ME, Wallen EM, Pruthi RS. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. *Eur Urol* 2010;57:196-201. [DOI PubMed](#)
12. Wijburg CJ, Michels CTJ, Hannink G, Grutters JPC, Rovers MM, Alfred Witjes J; RACE Study Group. Robot-assisted radical cystectomy versus open radical cystectomy in bladder cancer patients: a multicentre comparative effectiveness study. *Eur Urol* 2021;79:609-18. [DOI PubMed](#)
13. Asil E, Canda AE, Atmaca AF, et al. Outcomes and complications of radical cystectomy with ileal conduit urinary diversion: A comparison between open, semi-robotic and totally robotic surgery. *Int J Med Robot* 2021:e2221. [DOI PubMed](#)
14. Ip KL, Javier-DesLoges JF, Leung C, et al. Comparison of long-term outcomes in a 10-year experience of robotic cystectomy vs. open cystectomy. *J Robot Surg* 2020. [DOI PubMed](#)

15. Zhang JH, Ericson KJ, Thomas LJ, et al. Large single institution comparison of perioperative outcomes and complications of open radical cystectomy, intracorporeal robot-assisted radical cystectomy and robotic extracorporeal approach. *J Urol* 2020;203:512-21. [DOI](#) [PubMed](#)
16. Faraj KS, Abdul-Muhsin HM, Rose KM, et al. Robot assisted radical cystectomy vs open radical cystectomy: Over 10 years of the Mayo Clinic Experience. *Urol Oncol* 2019;37:862-9. [DOI](#) [PubMed](#)
17. Moschini M, Soria F, Mathieu R, et al; European Association of Urology - Young Academic Urologists (EAU-YAU); Urothelial Carcinoma Working Group. Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. *Urol Oncol* 2019;37:179.e171-7. [DOI](#) [PubMed](#)
18. Simone G, Tuderti G, Misuraca L, et al. Perioperative and mid-term oncologic outcomes of robotic assisted radical cystectomy with totally intracorporeal neobladder: Results of a propensity score matched comparison with open cohort from a single-centre series. *Eur J Surg Oncol* 2018;44:1432-8. [DOI](#) [PubMed](#)
19. Hanna N, Leow JJ, Sun M, et al. Comparative effectiveness of robot-assisted vs. open radical cystectomy. *Urol Oncol* 2018;36:88.e81-9. [DOI](#) [PubMed](#)
20. Gandaglia G, Karl A, Novara G, et al. Perioperative and oncologic outcomes of robot-assisted vs. open radical cystectomy in bladder cancer patients: a comparison of two high-volume referral centers. *Eur J Surg Oncol* 2016;42:1736-43. [DOI](#) [PubMed](#)
21. Tan WS, Sridhar A, Ellis G, et al. Analysis of open and intracorporeal robotic assisted radical cystectomy shows no significant difference in recurrence patterns and oncological outcomes. *Urol Oncol* 2016;34:257.e1-9. [DOI](#) [PubMed](#)
22. Matulewicz RS, DeLancey JO, Manjunath A, Tse J, Kundu SD, Meeks JJ. National comparison of oncologic quality indicators between open and robotic-assisted radical cystectomy. *Urol Oncol* 2016;34:431.e9-15. [DOI](#) [PubMed](#)
23. Nguyen DP, Al Hussein Al Awamlh B, Wu X, et al. Recurrence patterns after open and robot-assisted radical cystectomy for bladder cancer. *Eur Urol* 2015;68:399-405. [DOI](#) [PubMed](#) [PMC](#)
24. Atmaca AF, Canda AE, Gok B, Akbulut Z, Altinova S, Balbay MD. Open versus robotic radical cystectomy with intracorporeal Studer diversion. *JSLs* 2015;19:e2014.00193. [DOI](#) [PubMed](#) [PMC](#)
25. Elsayed AS, Gibson S, Jing Z, et al. Rates and patterns of recurrences and survival outcomes after robot-assisted radical cystectomy: Results from the International Robotic Cystectomy Consortium. *J Urol* 2021;205:407-13. [DOI](#) [PubMed](#)
26. Brassetti A, Cacciamani G, Anceschi U, et al. Long-term oncologic outcomes of robot-assisted radical cystectomy (RARC) with totally intracorporeal urinary diversion (ICUD): a multi-center study. *World J Urol* 2020;38:837-43. [DOI](#) [PubMed](#)
27. Hussein AA, Elsayed AS, Aldhaam NA, et al. Ten-year oncologic outcomes following robot-assisted radical cystectomy: Results from the International Robotic Cystectomy Consortium. *J Urol* 2019;202:927-35. [DOI](#) [PubMed](#)
28. Hussein AA, Saar M, May PR, et al. Early oncologic failure after robot-assisted radical cystectomy: Results from the International Robotic Cystectomy Consortium. *J Urol* 2017;197:1427-36. [DOI](#) [PubMed](#)
29. Collins JW, Hosseini A, Adding C, et al. Early recurrence patterns following totally intracorporeal robot-assisted radical cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group. *Eur Urol* 2017;71:723-6. [DOI](#) [PubMed](#)
30. Raza SJ, Wilson T, Peabody JO, et al. Long-term oncologic outcomes following robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. *Eur Urol* 2015;68:721-8. [DOI](#) [PubMed](#)
31. Hellenthal NJ, Hussain A, Andrews PE, et al. Lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. *BJU Int* 2011;107:642-6. [DOI](#) [PubMed](#)
32. Hellenthal NJ, Hussain A, Andrews PE, et al. Surgical margin status after robot assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. *J Urol* 2010;184:87-91. [DOI](#) [PubMed](#)
33. Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. *J Clin Oncol* 2004;22:2781-9. [DOI](#) [PubMed](#)
34. Wilson TG, Guru K, Rosen RC, et al. Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. *Eur Urol* 2015;67:363-75. [DOI](#) [PubMed](#)
35. Yuh B, Wilson T, Bochner B, et al. Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy. *Eur Urol* 2015;67:402-22. [DOI](#) [PubMed](#)
36. Marshall SJ, Hayn MH, Stegemann AP, et al. Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC). *BJU Int* 2013;111:1075-80. [DOI](#) [PubMed](#)
37. Rai BP, Bondad J, Vasdev N, et al. Robot-assisted vs open radical cystectomy for bladder cancer in adults. *BJU Int* 2020;125:765-79. [DOI](#) [PubMed](#)
38. Sathianathan NJ, Kalapara A, Frydenberg M, et al. Robotic assisted radical cystectomy vs open radical cystectomy: Systematic review and meta-analysis. *J Urol* 2019;201:715-20. [DOI](#) [PubMed](#)
39. Dotan ZA, Kavanagh K, Yossepowitch O, et al. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. *J Urol* 2007;178:2308-12; discussion 2313. [DOI](#) [PubMed](#)
40. Novara G, Svatek RS, Karakiewicz PI, et al. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. *J Urol* 2010;183:2165-70. [DOI](#) [PubMed](#)
41. Benson MC. Editorial comment. *J Urol* 2010;184:91. [DOI](#) [PubMed](#)
42. Karakiewicz PI, Shariat SF, Palapattu GS, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. *J Urol* 2006;176:1354-61; discussion 1361. [DOI](#) [PubMed](#)
43. Kluth LA, Rieken M, Xylinas E, et al. Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. *Eur Urol* 2014;66:913-9. [DOI](#) [PubMed](#)

44. Sonpavde G, Khan MM, Lerner SP, et al. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. *J Urol* 2011;185:456-61. [DOI](#) [PubMed](#)
45. Khetrpal P, Tan WS, Lamb B, et al. Port-site metastases after robotic radical cystectomy: A systematic review and management options. *Clin Genitourin Cancer* 2017;15:440-4. [DOI](#) [PubMed](#)
46. Nguyen DP, Al Hussein Al Awamlh B, O'Malley P, et al. Factors impacting the occurrence of local, distant and atypical recurrences after robot-assisted radical cystectomy: A detailed analysis of 310 patients. *J Urol* 2016;196:1390-6. [DOI](#) [PubMed](#)
47. Yuh B, Chan K, Wilson T. Robotic cystectomy-moving from innovation to measurable impact. *Eur Urol* 2018;74:472-3. [DOI](#) [PubMed](#)
48. Lau CS, Talug J, Williams SB, et al. Robotic-assisted laparoscopic radical cystectomy in the octogenarian. *Int J Med Robot* 2012;8:247-52. [DOI](#) [PubMed](#)
49. Tuderti G, Mastroianni R, Flammia S, et al. Sex-sparing robot-assisted radical cystectomy with intracorporeal Padua ileal neobladder in female: Surgical technique, perioperative, oncologic and functional outcomes. *J Clin Med* 2020;9:577. [DOI](#) [PubMed](#) [PMC](#)
50. Asimakopoulos AD, Campagna A, Gakis G, et al. Nerve sparing, robot-assisted radical cystectomy with intracorporeal bladder substitution in the male. *J Urol* 2016;196:1549-57. [DOI](#) [PubMed](#)
51. Koç E, Gök B, Gumuskaya B, Atmaca AF, Canda AE, Balbay MD. Robot assisted radical cystectomy outcomes in micropapillary and plasmacytoid variants. *Urol J* 2020;17:607-13. [DOI](#) [PubMed](#)
52. Catto JWF, Khetrpal P, Ambler G, et al. Robot-assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy (iROC): protocol for a randomised controlled trial with internal feasibility study. *BMJ Open* 2018;8:e020500. [DOI](#) [PubMed](#) [PMC](#)